SOX9 regulates ERBB signalling in pancreatic cancer development

Gut

Volumn 64, Issue 11, 2015, Pages 1790-1799

  Grimont, Adrien ^a   Pinho, Andreia V ^b,c   Cowley, Mark J ^b,c   Augereau, Cécile ^a   Mawson, Amanda ^b,c   Giry Laterrière, Marc ^b,c   Van Den Steen, Géraldine ^a   Waddell, Nicola ^c,d   Pajic, Marina ^b,c,e   Sempoux, Christine ^f   Wu, Jianmin ^b,c,e   Grimmond, Sean M ^c,d,g   Biankin, Andrew V ^b,c,e,g   Lemaigre, Frédéric P ^a   Rooman, Ilse ^b,c,e   Jacquemin, Patrick ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c Australian Pancreatic Cancer Genome Initiative ^*  (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTION FACTOR SOX9; EGFR PROTEIN, HUMAN; SOX9 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME REGULATION; GENOMICS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOX9 GENE; TRANSCRIPTOMICS; ADENOCARCINOMA; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; PANCREATIC NEOPLASMS; PHYSIOLOGY;

ADENOCARCINOMA; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR;

EID: 84947557981     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307075     Document Type: Article

References (42)

1. Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 2012;9:435-44.
2. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491:399-405.
3. Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol 2013;7:232-47.
4. Rooman I, Real FX. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Gut 2012;61:449-58.
5. Kopp JL, von Figura G, Mayes E, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 2012;22:737-50.
6. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83.
7. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
8. Pinho AV, Chantrill L, Rooman I. Chronic pancreatitis: a path to pancreatic cancer. Cancer Lett 2014;345:203-9.
9. Pinho AV, Rooman I, Reichert M, et al. Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis. Gut 2011;60:958-66.
10. Guerra C, Schuhmacher AJ, Canamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007;11:291-302.
11. Collins MA, Bednar F, Zhang Y, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012;122:639-53.
12. Ardito CM, Gruner BM, Takeuchi KK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012;22:304-17.
13. Navas C, Hernandez-Porras I, Schuhmacher AJ, et al. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012;22:318-30.
14. Shih HP, Kopp JL, Sandhu M, et al. A Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell differentiation. Development 2012;139:2488-99.
15. Prevot PP, Simion A, Grimont A, et al. Role of the ductal transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia. Gut 2012;61:1723-32.
16. Sun M, Li N, Dong W, et al. Copy-number mutations on chromosome 17q24.2-q24.3 in congenital generalized hypertrichosis terminalis with or without gingival hyperplasia. Am J Hum Genet 2009;84:807-13.
17. Coustry F, Oh CD, Hattori T, et al. The dimerization domain of SOX9 is required for transcription activation of a chondrocyte-specific chromatin DNA template. Nucleic Acids Res 2010;38:6018-28.
18. Sudbeck P, Schmitz ML, Baeuerle PA, et al. Sex reversal by loss of the C-terminal transactivation domain of human SOX9. Nat Genet 1996;13:230-2.
19. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
20. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-14.
21. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500-3.
22. Wu J, Mao X, Cai T, et al. KOBAS server: a web-based platform for automated annotation and pathway identification. Nucleic Acids Res 2006;34:W720-4.
23. Xie C, Mao X, Huang J, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res 2011;39:W316-22.
24. Storey JD. A direct approach to false discovery rates. J Royal Stat Soc B 2002;64:479-98.
25. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-50.
26. Liberzon A, Subramanian A, Pinchback R, et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011;27:1739-40.
27. Kist R, Schrewe H, Balling R, et al. Conditional inactivation of Sox9: a mouse model for campomelic dysplasia. Genesis 2002;32:121-3.
28. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
29. Desai BM, Oliver-Krasinski J, De Leon DD, et al. Preexisting pancreatic acinar cells contribute to acinar cell, but not islet beta cell, regeneration. J Clin Invest 2007;117:971-7.
30. Prévot PP, Augereau C, Simion A, et al. Let-7b and miR-495 stimulate differentiation and prevent metaplasia of pancreatic acinar cells by repressing HNF6. Gastroenterology 2013;145:668-78 e3.
31. Cui J, Germer K, Wu T, et al. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res 2012;72:5625-34.
32. Borg JP, Marchetto S, Le Bivic A, et al. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol 2000;2:407-14.
33. Tao Y, Dai P, Liu Y, et al. Erbin regulates NRG1 signaling and myelination. Proc Natl Acad Sci USA 2009;106:9477-82.
34. Oh CD, Maity SN, Lu JF, et al. Identification of SOX9 interaction sites in the genome of chondrocytes. PLoS ONE 2010;5:e10113.
35. Means AL, Meszoely IM, Suzuki K, et al. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 2005;132:3767-76.
36. Shi G, Direnzo D, Qu C, et al. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene 2013;32:1950-8.
37. Li Y, Macdonald-Obermann J, Westfall C, et al. Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization. J Biol Chem 2012;287:31116-25.
38. Safran H, Iannitti D, Ramanathan R, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004;22:706-12.
39. Harder J, Ihorst G, Heinemann V, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012;106:1033-8.
40. Chou A, Waddell N, Cowley MJ, et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med 2013;5:78.
41. Maron R, Schechter B, Mancini M, et al. Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci USA 2013;110:15389-94.
42. Li Y, Zheng M, Lau YF. The Sex-Determining Factors SRY and SOX9 Regulate Similar Target Genes and Promote Testis Cord Formation during Testicular Differentiation. Cell Rep 2014;8:723-33.